2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
LifeVantage reported fourth-quarter and full fiscal 2026 results (year ended June 30, 2026) showing sharp declines in revenue and profit from the prior year. The company is not issuing formal fiscal 2027 guidance because of the recent transition in its Chief Executive Officer role, leaving shareholders without a company forecast for the coming year.
Fiscal 2026 revenue was $182.6 million, down 20.1% from $228.5 million in fiscal 2025; Americas revenue fell 23.2%.
Fourth-quarter revenue was $42.4 million, down 23.1%, and diluted EPS was $0.10 versus $0.15 a year earlier.
Fiscal 2026 diluted EPS was $0.40 versus $0.75; adjusted EPS was $0.56 versus $0.82.
No formal fiscal 2027 guidance was issued due to the recent CEO transition; Terrence Moorehead is President and CEO.
Titan Machinery reported fiscal second-quarter revenue of $496.4 million, down from $546.4 million a year earlier, and a net loss of $9.2 million, or $0.40 per diluted share, versus a $6.0 million loss, or $0.26 per share, last year. The company reaffirmed its fiscal 2027 profitability outlook but cut its Europe segment revenue assumption, so weaker sales and losses point to pressure on shareholder returns.
Gross profit margin rose to 18.6% from 17.1%, but gross profit slipped to $92.4 million from $93.6 million.
Adjusted EBITDA was $4.6 million, compared with $5.6 million a year earlier.
Europe fiscal 2027 revenue assumption was revised to down 30% to 40%, from down 20% to 25%; the company reaffirmed adjusted EBITDA of $17.0 million to $29.0 million.
Net cash used for operating activities was $25.1 million for the six months ended July 31, 2026, compared with $49.9 million provided a year earlier.
Vyome Holdings reported its second-quarter 2026 results, showing a net loss of approximately $720,000, or $0.10 per share, and total operating expenses of approximately $874,000. The company's cash and cash equivalents rose to approximately $7.9 million from $5.0 million at December 31, 2025, but the six-month net loss widened to $1,705,204 from $602,732 a year earlier, and six-month revenue fell to $58,546 from $248,535.
Q2 2026 net loss attributable to common shareholders: approximately $720,000, or $0.10 per basic and diluted share
Cash and cash equivalents: approximately $7.9 million at June 30, 2026, up from $5.0 million at December 31, 2025
Six-month net loss: $1,705,204 in 2026 versus $602,732 in 2025; six-month revenues: $58,546 versus $248,535
Company received the FDA's written response on its VT-1953 clinical development program during the second quarter
The Cato Corporation reported second-quarter 2026 net income of $1.1 million, or $0.06 per diluted share, down from $6.8 million, or $0.35, a year earlier, as sales fell 6% to $163.9 million. Chairman and CEO John Cato said pressure on customers' discretionary income will continue and that he anticipates the back half of 2026 to be challenging, which weighs on the outlook for shareholders.
Q2 sales were $163.9 million, down 6% from $174.7 million, with same-store sales down 3.7%.
Q2 gross margin fell to 32.8% of sales from 36.2% due to lower merchandise margins and occupancy cost deleverage.
Six-month net income was $10.5 million, or $0.53 per diluted share, versus $10.1 million, or $0.51, a year earlier, on sales down 2.9% to $333.3 million.
The company closed eight stores in the quarter and had 1,057 stores as of August 1, 2026, versus 1,101 a year earlier.
PermRock Royalty Trust declared a monthly cash distribution of $265,001.53, or $0.021782 per Trust Unit, to holders of record on August 31, 2026, payable September 15, 2026, based mainly on June 2026 production. The filing shows lower oil cash receipts and higher operating expenses than the prior month, which reduce the net profits available to the Trust and its unitholders.
Distribution: $265,001.53 total, $0.021782 per Trust Unit; record date August 31, 2026; payment date September 15, 2026
Oil cash receipts were $1.42 million, down $0.16 million from the prior month, mainly due to lower oil prices
Average oil price was $88.13 per barrel, versus $104.89 in the prior month
Total direct operating expenses rose $0.17 million to $0.66 million, mainly from higher lease operating and workover expenses
Solésence said on August 17, 2026 that its previously issued financial statements from December 31, 2023 through March 31, 2026 should no longer be relied upon and must be restated. The errors involved how labor and overhead were allocated to inventory, which overstated inventories and misstated cost of revenue, and the filing says the errors also affected gross profit, net income (loss), earnings per share and stockholders' equity.
Ten periods are affected, from December 31, 2023 through March 31, 2026, per the Audit Committee, Board and executive officers' August 17, 2026 conclusion.
The errors relate to labor and overhead allocation in inventories, which the company says did not comply with ASC 330 inventory-costing requirements.
The company expects to amend its 10-K reports for 2023, 2024 and 2025 and several 10-Q reports in the coming weeks.
The 8-K is dated August 20, 2026, and was signed by CFO Laura Riffner; the Audit Committee discussed the matters with its independent accountant.
Hovnanian reported fiscal third-quarter 2026 revenue of $705.7 million, down from $800.6 million a year earlier, and a net loss available to common stockholders of $4.5 million, or $0.70 per diluted share, compared with net income of $13.9 million, or $1.99 per share. Management said adjusted pretax results came in below its guided range, and it issued fourth-quarter guidance for revenue of $800 million to $900 million.
Q3 total revenues were $705.7 million versus $800.6 million in the prior-year quarter; the company said this was within its guidance range.
Net loss available to common stockholders was $4.5 million, or $0.70 per diluted share, versus net income of $13.9 million, or $1.99 per share, a year earlier.
Adjusted loss before income taxes was $2.3 million, compared with adjusted income of $39.8 million in the third quarter of fiscal 2025; adjusted EBITDA was $31.9 million, within guidance.
Fourth-quarter fiscal 2026 guidance: total revenues of $800 million to $900 million, adjusted income before income taxes of $15 million to $30 million, and adjusted EBITDA of $50 million to $65 million.
Exyn Technologies reported second-quarter 2026 revenue of $950 thousand, down from $1.4 million a year earlier, and a net loss of $6.9 million, up from $2.9 million, although gross margin rose to 46.9%. The same day, the company said Chief Operating Officer Ben Williams would serve as interim chief executive and independent director Gregory McNeal as chairman, following the resignation of Brandon Torres Declet as CEO and chairman, which adds leadership change to weaker results for shareholders.
Revenue was $950 thousand in Q2 2026 versus $1.4 million in Q2 2025; the company cited the timing of customer deployments.
Net loss was $6.9 million, or $1.55 per share, versus $2.9 million, or $2.22 per share, a year earlier.
Gross margin rose 630 basis points to 46.9%; cash and cash equivalents were about $7.8 million as of June 30, 2026.
Ben Williams was appointed interim CEO and Gregory McNeal chairman, both effective August 19, 2026.
Iridex reported second-quarter 2026 revenue of $12.6 million, down 7% from a year earlier, as lower retina sales outweighed growth in its Cyclo G6 glaucoma products. The net loss widened to $1.3 million, or $0.07 per share, from $1.0 million, or $0.06 per share, and the company reaffirmed its full-year 2026 revenue guidance of $51 million to $53 million.
Total revenue was $12.6 million, compared with $13.6 million in the prior-year quarter; retina product revenue fell to $6.5 million from $8.0 million.
Cyclo G6 product family revenue rose 19% to $3.9 million, with 17,700 probes sold versus 13,100 a year earlier.
Net loss was $1.3 million, or $0.07 per share, versus $1.0 million, or $0.06 per share, in the second quarter of 2025.
Full-year 2026 revenue guidance of $51 million to $53 million was reaffirmed; adjusted operating expense guidance is $19 million to $19.5 million.
Toll Brothers reported fiscal third-quarter 2026 results for the period ended July 31, 2026, with net income of $280.1 million, or $2.97 per diluted share, down from $369.6 million, or $3.73, a year earlier. Home sales revenues fell to $2.65 billion from $2.88 billion, and the company reaffirmed its full-year guidance while raising its projected fiscal 2026 share repurchases to $700 million from $650 million.
Net income was $280.1 million, or $2.97 per diluted share, versus $369.6 million, or $3.73, in the prior-year third quarter.
Home sales revenues were $2.65 billion on 2,662 delivered homes, compared with $2.88 billion on 2,959 homes a year earlier.
Home sales gross margin was 23.9%, versus 25.6%; adjusted home sales gross margin was 25.6%, versus 27.5%.
Full-year fiscal 2026 guidance was reaffirmed, including about $10.5 billion of home sales revenues, and projected share repurchases were raised to $700 million.
La-Z-Boy reported fiscal first-quarter 2027 results for the period ended July 25, 2026. Sales fell 3% to $476 million, GAAP results swung to a loss of $(0.06) per diluted share from $0.44 a year earlier, and adjusted diluted EPS fell to $0.43 from $0.47, while Retail written sales rose 16%. The company also gave second-quarter sales guidance of $500-$520 million and an adjusted operating margin of 4.0-5.5%.
Consolidated sales of $475.7 million fell 3% from $492.2 million; Wholesale sales fell 9% to $323 million, while Retail delivered sales rose 10% to $229 million
GAAP diluted EPS was $(0.06) versus $0.44; adjusted diluted EPS was $0.43 versus $0.47, with adjustments mainly for $17.6 million of charges tied to exiting two smallest plants
Second-quarter outlook: sales of $500-$520 million and adjusted operating margin of 4.0-5.5%
Board declared a quarterly dividend of $0.242 per share, payable September 15, 2026, to holders of record on September 3, 2026; the company returned $35 million to shareholders in the quarter
Flexible Solutions International reported a second-quarter 2026 net loss of $1,912,967, or $0.15 per share, versus net income of $2,028,912, or $0.16 per share, a year earlier. Sales fell about 14% to $7,610,148, and management said scale-up costs for food-grade and Panama operations outweighed revenue so far, with the company expecting a return to profitability in Q3 2026.
Q2 2026 sales were $7,610,148, down about 14% from $8,867,132 in Q2 2025, which included a $2.5 million R&D payment not repeated in 2026.
Q2 2026 net loss was $1,912,967 ($0.15 per share), compared with net income of $2,028,912 ($0.16 per share) in Q2 2025.
Management guided that Panama revenue could reach $3 million, ENP revenue could exceed $5 million, and NanoChem revenue could exceed $4 million in Q3 2026.
Management expects to raise prices to customers in the third or fourth quarter unless oil prices fall significantly.
Sypris Solutions reported second-quarter 2026 revenue of $30.3 million, down from $31.4 million a year earlier, and a net loss of $3.1 million, or $0.14 per share, compared with a loss of $2.1 million, or $0.09 per share, in the prior-year quarter. The company cited material availability issues and customer design changes at Sypris Electronics, and said orders rose 25% sequentially, with management expecting operations to improve through 2026.
Revenue was $30.3 million for the quarter ended July 5, 2026, versus $31.4 million a year earlier.
Sypris Electronics revenue fell to $15.5 million from $17.3 million, and it posted a gross loss of $0.8 million.
Net loss for the six months was $7.2 million, or $0.32 per share, compared with $3.0 million, or $0.13 per share, a year earlier.
Sypris Technologies revenue rose to $14.9 million from $14.1 million, and its gross profit increased to $2.7 million from $2.1 million.
Elauwit Connection reported second-quarter 2026 revenue of $2.9 million, down 46% from $5.3 million a year earlier, and a net loss of $3.1 million, compared with $0.9 million in the prior-year quarter. The company attributed the revenue decline to the timing of construction projects, which it expects to weight toward the second half of 2026, and said contracted units rose 33% year over year to 42,687.
Q2 2026 revenue was $2.9 million, down from $5.3 million in Q2 2025; six-month revenue was $7.3 million, down from $10.8 million.
Q2 2026 net loss was $3.1 million ($0.47 per share), compared with $0.9 million ($0.17 per share) a year earlier.
Contracted units reached 42,687 at June 30, 2026, up 33% year over year; billed units rose 163% to 22,967.
As of June 30, 2026, cash and cash equivalents were $1.2 million and total debt was $2.2 million.
Pioneer Power Solutions reported second-quarter 2026 revenue of $5.0 million, down 40.0% from $8.4 million a year earlier, mainly due to lower e-Boost mobile EV charging sales and rentals. The net loss widened to $2.1 million from $1.3 million, and management projects about $15.0 million of revenue in the second half of 2026, which depends on converting its $18.4 million backlog into sales.
Q2 2026 revenue was $5.0 million versus $8.4 million in Q2 2025, a decrease of 40.0%, primarily due to lower e-Boost sales and rentals.
Net loss was $2.1 million, or $0.19 per share, compared with $1.3 million, or $0.12 per share, in the year-ago quarter.
Backlog was $18.4 million at June 30, 2026, up from $13.9 million at March 31, 2026.
Management expects revenue of approximately $15.0 million for the second half of 2026, growth of more than 60% over the first half; the company had $10.7 million of cash and no bank debt at June 30, 2026.
NexGel reported second quarter 2026 revenue of $3.69 million and a net loss of $2.87 million, and said its integration and expansion into the surgical channel have moved more slowly than expected. Shareholders did not give sufficient support to the proposed increase in authorized shares and reverse stock split, and the company plans to resubmit them as standalone proposals with completion expected in late September.
Q2 2026 revenue of $3.69 million and net loss of $2.87 million, including $756,554 of BioNX intangible amortization and $273,710 of one-time transaction expenses
BioNX Surgical backlog of approximately $795,000 due to supply chain constraints
Proxy proposals for increased authorized shares and reverse split lacked sufficient support; resolicitation timeline anticipates completion in late September
Investor update call expected on or around September 15, 2026
InspireMD reported second quarter 2026 revenue of $1.8 million, flat year over year, with a gross loss of $774,000 after a U.S. recall of the CGuard Prime 135 cm delivery system. The net loss was $14.3 million, or $0.17 per share, compared with $13.2 million, or $0.26 per share, a year earlier, and cash and marketable securities fell to $30.4 million by June 30, 2026.
Q2 2026 total revenue was $1,771,000, down 0.4% from $1,778,000; international revenue rose 21% to $2,122,000 while U.S. revenue was negative at $(351,000) due to $734,000 of recall customer credits.
Q2 2026 net loss was $14,324,000, or $0.17 per share, versus $13,151,000, or $0.26 per share, in Q2 2025.
Cash and cash equivalents and marketable securities were $30,421,000 at June 30, 2026, compared with $54,211,000 at December 31, 2025.
The company said it initiated cost-saving actions after the quarter ended, expected to generate annual savings of approximately $9 million.
Retractable Technologies reported second-quarter 2026 net sales of $7.2 million, down from $10.4 million a year earlier, with an operating loss of $5.1 million in both periods. The company attributed the sales decline mainly to the timing of EasyPoint needle orders and to unusually high flu season unit sales in the second quarter of 2025. Second-quarter net income of $2.8 million was driven by a $6.4 million gain on the sale of equity securities, while the first half shows a net loss of $1.4 million and a wider operating loss of $11.3 million.
Q2 2026 net sales were $7.2 million versus $10.4 million in Q2 2025; operating loss was $5.1 million in both periods.
First-half 2026 net sales were $14.4 million versus $18.7 million; operating loss widened to $11.3 million from $9.8 million.
Q2 2026 net income of $2.8 million included a $6.4 million realized gain on sale of equity; first-half net loss was $1.4 million.
A reduction in force in April 2026 is expected to produce cost savings in future periods.
Nakamoto reported second-quarter 2026 results on August 13, 2026, with total operating revenue of $35.9 million, an operating loss of $149.1 million, and a net loss of $133.0 million, or $6.65 per diluted share. The company said the losses were driven mainly by $105.2 million of non-cash goodwill impairment charges and $48.7 million of mark-to-market losses on digital assets. Shareholders face a large GAAP loss even though the company reported $7.3 million of adjusted operating income and reduced debt by about $45 million.
Total operating revenue was $35.9 million for the quarter ended June 30, 2026; the prior-year quarter shows no revenue figures in the filing.
Net loss was $133.0 million, or $6.65 per diluted share, compared with a net loss of $2.4 million in the second quarter of 2025.
Adjusted operating income, a non-GAAP measure, was $7.3 million, which the company said was its first positive adjusted operating income since becoming a Bitcoin operating company.
As of June 30, 2026, the company held 4,467 Bitcoin with an aggregate fair value of approximately $261.5 million and authorized a share repurchase program of up to $25 million.
Traws Pharma reported its quarter ended June 30, 2026, with no revenue, compared with $2.7 million a year earlier, and a net loss of $3.0 million, or $0.16 per share, versus a $0.9 million loss, or $0.11 per share, in the same period of 2025. The company said its cash and equivalents, plus expected at-the-market equity proceeds, should fund operations into the first quarter of 2027, and that it may need additional financing after that.
Q2 2026 revenue was zero, down from $2.7 million in Q2 2025, which included a non-recurring deferred revenue recognition tied to a licensing termination.
Q2 2026 net loss was $3.0 million ($0.16 per share); six-month net loss was $10.2 million, compared with $20.6 million net income in the first half of 2025, which included a $26.7 million non-cash warrant gain.
Cash and cash equivalents were $5.0 million at June 30, 2026, up from $3.8 million at December 31, 2025, mainly from the April 2026 private placement and ATM sales.
Shareholders approved the Series B and Series C financing tranches on July 8, 2026; the company says access remains subject to milestones and investor participation, and the FDA clinical hold on tivoxavir marboxil is still pending resolutio
Cerenome reported second quarter 2026 results on August 14, 2026. Grant revenue fell to $0.4 million from $1.4 million a year earlier, the operating loss widened to $9.1 million from $1.5 million, and the company posted a net loss of $9.0 million, or $1.31 per basic share, compared with net income of $5.2 million in the prior-year quarter, which included a $6.5 million gain from a change in fair value of derivative instruments. Cash and investments totaled $8.6 million at June 30, 2026, and the company affirmed its 2026 milestones and outlook without changes.
Operating loss was $9.1 million in Q2 2026 versus $1.5 million in Q2 2025, which the company attributes mainly to expansion of CNSide commercial operations and funding of the REYOBIQ Phase 2 trial.
Net loss was $9.0 million, or $1.31 per basic share, versus net income of $5.2 million, or $0.62 per basic share, in Q2 2025.
Cash, cash equivalents and investments were $8.6 million as of June 30, 2026.
The company affirmed its 2026 milestones, including ReSPECT-GBM data expected in Q1 2027.
Smith-Midland reported second-quarter 2026 revenue of $23.4 million, down from $26.2 million a year earlier, and net income of $1.4 million, or $0.26 per diluted share, down from $4.2 million, or $0.79. The company attributed the decline mainly to a higher-margin special barrier rental project in the 2025 quarter that did not recur. Backlog was approximately $57.4 million as of August 1, 2026, up from $54 million a year earlier.
Revenue was $23.4 million versus $26.2 million; product sales were $11.2 million versus $13.4 million.
Gross margin was 23.2% versus 29.7%, mainly due to the special barrier rental project in Q2 2025 that did not recur.
Net income was $1.4 million, or $0.26 per diluted share, versus $4.2 million, or $0.79 per diluted share.
Backlog was approximately $57.4 million as of August 1, 2026, compared with $54 million one year earlier.
Enveric Biosciences reported a second-quarter 2026 net loss of $3.0 million, up from $2.5 million a year earlier, and cash on hand of $8.3 million as of June 30, 2026. The company also gave an update on its lead drug candidate EB-003, including preclinical data and the start of genotoxicity studies ahead of a planned IND submission.
Net loss attributable to stockholders was $3.0 million for the quarter ended June 30, 2026, versus $2.5 million a year earlier.
Basic and diluted loss per share was $0.76, compared with $11.65 in the second quarter of 2025.
The company raised $5.0 million in gross offering proceeds and $1.5 million from warrant exercises in the quarter.
Genotoxicity studies for EB-003 were initiated, a step the filing describes as required for IND submission.
LeonaBio reported a second-quarter 2026 net loss of $19.0 million, or $0.80 per share, up from $7.0 million, or $1.78 per share, a year earlier. The company said higher spending on the Phase 3 ELAINE-3 trial for lasofoxifene drove the increase, and cash, cash equivalents and investments fell to $51.1 million as of June 30, 2026, which shareholders may want to track against the company's funding needs.
Net loss was $19.0 million, or $0.80 per share, for the quarter ended June 30, 2026, compared with $7.0 million, or $1.78 per share, a year earlier.
R&D expenses rose to $12.9 million from $3.7 million, driven mainly by clinical trial spend for the ELAINE-3 trial.
Cash, cash equivalents and investments were $51.1 million at June 30, 2026, down from $88.3 million at December 31, 2025; net cash used in operations was $37.9 million for the quarter.
CSP Inc. (CSPi) reported fiscal third-quarter 2026 results for the quarter ended June 30, 2026, with sales of $14.4 million, down from $15.4 million a year earlier, and a net loss of $846,000, or $0.09 per share, compared with a net loss of $264,000, or $0.03 per share, in the prior-year quarter. Gross profit margin rose to 30.1% from 28.8%, and management said vendor hardware delivery delays are likely to continue into the first half of fiscal 2027. For shareholders, the quarter shows lower sales and a wider loss, while the board declared a quarterly dividend of $0.03 per share.
Third-quarter sales were $14.4 million, versus $15.4 million a year earlier; gross profit margin was 30.1% versus 28.8%.
Net loss was $846,000, or $0.09 per share, versus a net loss of $264,000, or $0.03 per share, a year earlier.
Nine-month net loss was $491,000, or $0.05 per share, compared with net income of $100,000, or $0.01 per diluted share, a year earlier.
Cash and cash equivalents were $24.7 million as of June 30, 2026; the board declared a $0.03 dividend payable September 15, 2026, to holders of record on August 28, 2026.
Sinda Ltd., a silver exploration company listed on the NYSE, reported a second-quarter 2026 net loss of $16.6 million, compared with $2.2 million in the same quarter of 2025. The company attributed the increase to planned spending on its Phase 1 surface drilling program and higher general and administrative costs tied to its IPO. The filing reports no revenue figures, and shareholders' main takeaway is that the company raised $331.3 million in total gross proceeds and reports a combined post-IPO liquidity position of $320.7 million.
Net loss of $16.6 million for the three months ended June 30, 2026, versus $2.2 million in Q2 2025
Total gross proceeds of $331.3 million from the IPO, the July 15, 2026 overallotment exercise, and the Fresnillo concurrent placement
Cash of approximately $204.3 million at June 30, 2026; combined post-IPO liquidity of $320.7 million
Phase 1 surface drilling completed 60,810 meters; the exploration decline received environmental authorization in March 2026 with construction targeted for 2H 2026
Upland Software reported second quarter 2026 revenue of $49.1 million, down 8% year over year, and a GAAP net loss of $35.3 million after a non-cash goodwill impairment. The company cut its full-year 2026 revenue and Adjusted EBITDA outlook relative to 2025, with both expected to decline at the midpoint, so shareholders face weaker reported results and a lower near-term earnings base.
Q2 2026 total revenue was $49.1 million, down from $53.4 million, mainly due to divestitures completed in 2025.
GAAP net loss was $35.3 million versus $13.0 million a year earlier, driven by a $35.2 million non-cash impairment of goodwill and other intangibles recorded in June 2026.
Full-year 2026 revenue guidance is $190.1 million to $196.1 million, an 11% decline at the midpoint; Adjusted EBITDA guidance is $49.8 million to $52.8 million, a 12% decline at the midpoint.
Adjusted EBITDA was $12.8 million in Q2 2026 versus $13.6 million a year earlier, and cash on hand was $31.0 million at June 30, 2026.
Tvardi Therapeutics reported a second-quarter 2026 net loss of $6.5 million, compared with net income of $4.2 million a year earlier, which included a $12.7 million non-cash gain. The company also reported topline healthy volunteer results for TTI-109, selected ulcerative colitis as its initial indication, and said its cash runway reaches the HCC readout in the third quarter of 2027, with additional funding needed to advance TTI-109 in UC.
Net loss of $6.5 million for the quarter ended June 30, 2026, versus net income of $4.2 million in the same period of 2025; basic and diluted loss per share was $(0.69).
Research and development expenses fell to $4.0 million from $5.8 million, and general and administrative expenses fell to $2.6 million from $3.1 million.
Cash, cash equivalents and short-term investments were $15.8 million at June 30, 2026, down from $30.8 million at December 31, 2025.
A KOL webinar on TTI-109 in UC is scheduled for August 19, 2026; the UC trial start is planned for 2027, subject to IND clearance and additional funding.
VirTra reported second-quarter 2026 results on August 13, 2026, with revenue down 17% year over year to $5.8 million and a net loss of $0.3 million, compared with net income of $0.2 million a year earlier. The company said several customers booked in late 2025 could not accept delivery in the first half of 2026, and it ended June with $24.9 million in total backlog.
Q2 2026 revenue was $5.8 million, down from $7.0 million; gross margin was 59%, versus 69% a year earlier.
Q2 net loss was $0.3 million, or $0.02 per diluted share, compared with net income of $0.2 million, or $0.02 per share, in Q2 2025.
Six-month revenue was $9.2 million, down 35% from $14.1 million, and the six-month net loss was $1.6 million, or $0.14 per diluted share.
Total backlog at June 30, 2026 was $24.9 million, including $13.2 million in capital, $3.8 million in service, and $7.9 million in STEP contracts.
AirJoule Technologies reported a second-quarter 2026 net loss of $8.5 million, or $0.12 per share, compared with net income of $2.5 million, or $0.04 per share, a year earlier. The company also raised its expected 2026 combined cash spend to $27 million to $28 million, up from about $25 million previously, and signed an exclusive sales agreement with Kubota Corporation. Shareholders face a wider loss and higher planned spending, while the company reports $41.4 million of cash and no debt.
Q2 2026 net loss of $8.5 million, or $0.12 per share, versus net income of $2.5 million, or $0.04 per share, in Q2 2025.
Six-month net loss of $58.4 million, or $0.85 per share, includes a $65.7 million equity loss from the investment in AirJoule, LLC.
2026 combined cash spend now expected at $27 million to $28 million, up from about $25 million previously.
Cash of $41.4 million at June 30, 2026; Kubota agreement covers deployments in Texas and California beginning in Q3 2026.
Lument Finance Trust reported a GAAP net loss attributable to common shareholders of $9.2 million, or $0.18 per share, for the quarter ended June 30, 2026, and a Distributable Loss of $5.3 million, or $0.10 per share. The board also approved a 1-for-10 reverse stock split, which the company says is intended to regain compliance with New York Stock Exchange listing requirements; for shareholders, the number of shares falls from about 52.5 million to about 5.3 million while ownership percentages are unchanged apart from cash paid for fractional shares.
Q2 2026 GAAP net loss attributable to common shareholders of $9.2 million, or $0.18 per share
Q2 2026 Distributable Loss of $5.3 million, or $0.10 per share, versus Distributable Earnings of $0.02 per share in Q1 2026
Reverse split expected to take effect at 5:00 pm ET on September 9, 2026, with split-adjusted trading beginning September 10, 2026 under ticker LFT
Book value per share of common stock was $2.76 as of June 30, 2026, down from $2.97 in the prior quarter; a $0.04 per share common dividend was declared
KinderCare reported second-quarter 2026 revenue of $697.5 million, down 0.4% from a year earlier, and a net loss of $8.8 million, compared with net income of $38.6 million in the second quarter of 2025. The company also updated its full-year 2026 guidance, but the filing does not state the prior ranges, so the direction of the change cannot be determined from this document.
Revenue of $697.5 million vs. $700.1 million in Q2 2025; center enrollment fell 4.0%
Net loss of $8.8 million, or $0.07 per diluted share, vs. net income of $38.6 million, or $0.33, a year earlier
Adjusted EBITDA of $63.0 million, down 23.6%; impairment losses rose $20.7 million and 49 centers closed in Q2
Full-year 2026 guidance: revenue $2.66 billion to $2.70 billion; adjusted EBITDA $200 million to $220 million; adjusted EPS $0.05 to $0.15
KULR Technology Group reported second quarter 2026 results that worsened on the headline measures: revenue fell 43% year over year and the company posted a net loss of $21,970,816, compared with net income a year earlier. The company attributed the loss mainly to a $10,591,667 fair value loss on its bitcoin holdings and said it has since exited Bitcoin mining and repaid its Coinbase loan in full.
Revenue decreased 43% to $2,080,177 in the quarter ended June 30, 2026, from $3,652,471 a year earlier.
Net loss was $21,970,816, or $0.47 per share, versus net income of $8,142,149, or $0.22 per share, a year earlier.
Loss from operations rose 19% to $11,204,578; gross margin was (31)% versus 20% a year earlier.
Cash balance was $12.8 million as of June 30, 2026; the company says it did not issue any shares through its ATM in the first half of 2026.
Sensus Healthcare reported second-quarter 2026 revenue of $2.3 million, down $5.0 million from the prior-year quarter, and a net loss of $8.7 million, or $0.53 per share. The company said a sale of eight units was not recorded in Q2 because of financing approval timing and will be recognized in Q3, while a $5.7 million tax expense that includes a valuation allowance against deferred tax assets added to the loss.
Q2 2026 revenue was $2.3 million versus $7.3 million in Q2 2025, with 11 units sold compared with 19 a year earlier.
Net loss was $8.7 million, or $0.53 per share, compared with a net loss of $1.0 million, or $0.06 per share, in Q2 2025.
Adjusted EBITDA, a non-GAAP measure, was negative $3.0 million versus negative $1.8 million a year earlier.
Cash, restricted cash and cash equivalents fell to $15.2 million at June 30, 2026, from $18.3 million at March 31, 2026.
Inhibrx reported second-quarter 2026 results showing a net loss of $36.7 million, or $2.34 per share, compared with $28.7 million, or $1.85 per share, a year earlier. The company recognized no revenue in the quarter, down from $1.3 million in the second quarter of 2025, and higher interest expense on its loan contributed to the larger loss.
Net loss of $36.7 million ($2.34 per share) vs. $28.7 million ($1.85 per share) in Q2 2025
No revenue in Q2 2026 vs. $1.3 million in Q2 2025 from the Scithera license transfer
R&D expense rose to $23.9 million from $22.3 million; G&A rose to $8.3 million from $6.4 million
Cash was $133.3 million at June 30, 2026, and $219.5 million as of August 6, 2026, after $100.0 million was funded under the Oxford loan amendment on July 15, 2026
Arcadia Biosciences reported second-quarter 2026 revenue of $1.4 million, down 1% from a year earlier, and a net loss attributable to common stockholders of $6.3 million, up from $4.5 million. The company attributed the revenue shortfall to low inventory and longer-than-expected shipping times, and the larger loss to non-operating items including a $5.4 million valuation loss on its June 2026 private placement and a $2.8 million unrealized loss on its Above Food stock.
Q2 2026 total revenues were $1.443 million versus $1.455 million in Q2 2025.
Q2 2026 net loss per share was $2.09, compared with $3.26 in Q2 2025.
The company raised $4 million in gross proceeds through a June 2026 private placement and reported $4.2 million in cash at June 30, 2026.
Alumis reported a net loss of $142.2 million for the quarter ended June 30, 2026, compared with net income of $59.3 million a year earlier, which included a $187.9 million non-operating gain tied to its ACELYRIN merger. The company took a $41.8 million impairment on the lonigutamab program after deciding to explore strategic alternatives for it, and reaffirmed that its $502.3 million in cash and marketable securities should fund operations into the fourth quarter of 2027.
Net loss of $142.2 million for the quarter, versus net income of $59.3 million a year earlier, which included a $187.9 million ACELYRIN merger gain.
Collaboration revenue of $1.7 million, down from $2.7 million a year earlier.
$41.8 million impairment loss on the acquired IPR&D intangible asset for the lonigutamab program.
Cash, cash equivalents and marketable securities of $502.3 million as of June 30, 2026; NDA submission for envudeucitinib in psoriasis planned for Q4 2026.
Capricor reported a second-quarter 2026 net loss of $40.7 million, or $0.70 per share, up from $25.9 million, or $0.57 per share, a year earlier, with no revenue recognized. The company said its FDA Advisory Committee voted 3 in favor and 9 against on cardiomyopathy efficacy for Deramiocel, and it is still working with the FDA on the Biologics License Application.
Q2 2026 net loss of $40.7 million, or $0.70 per share, versus $25.9 million, or $0.57 per share, in Q2 2025
Cash, cash equivalents and marketable securities of $237.9 million at June 30, 2026, down from $318.1 million at December 31, 2025
On July 29, 2026, the FDA Cellular, Tissue and Gene Therapies Advisory Committee voted 3 in favor and 9 against; the vote is advisory and non-binding
NS Pharma preliminary injunction motion withdrawn; the company estimates arbitration will begin this fall
4DMT reported a second-quarter 2026 net loss of $72.9 million, up from $54.7 million a year earlier, as research and development spending rose to $68.3 million from $48.0 million on its 4D-150 Phase 3 wet AMD trials. Collaboration revenue was $3.8 million, compared with an insignificant amount a year earlier. The company had $430.6 million in cash and marketable securities at June 30, 2026, and said this should fund operations into the second half of 2028, after securing a credit facility of up to $200 million from Hercules Capital with a $20 million initial draw.
Net loss was $72.9 million, or $1.04 per share, for the three months ended June 30, 2026, versus $54.7 million, or $0.98 per share, a year earlier.
R&D expenses were $68.3 million versus $48.0 million; G&A expenses were $12.5 million versus $11.5 million.
Cash, cash equivalents and marketable securities were $430.6 million at June 30, 2026, down from $514.0 million at December 31, 2025.
Hercules Capital credit facility of up to $200 million; initial draw of $20 million at closing.
Digimarc reported second-quarter 2026 results with total revenue of $7.4 million, down from $8.0 million a year earlier, and a GAAP net loss of $12.1 million, or $0.54 per diluted share, versus $8.2 million, or $0.38 per share, in the prior-year quarter. Ending annual recurring revenue fell to $11.6 million from $15.9 million, which matters to shareholders because it signals lower contracted revenue ahead, while the company's non-GAAP net loss narrowed to $1.7 million.
Total revenue was $7.4 million for Q2 2026 versus $8.0 million for Q2 2025.
GAAP net loss was $12.1 million ($0.54 per diluted share) versus $8.2 million ($0.38 per share).
Ending ARR was $11.6 million at June 30, 2026, versus $15.9 million a year earlier, reflecting a contract that expired in October 2025 and a June 2026 step-down.
Q2 operating expenses included $5.4 million of one-time stock-based compensation tied to accelerated equity awards for the former CEO, and cash, equivalents and marketable securities were $8.8 million at June 30, 2026.
Akari Therapeutics reported second quarter 2026 results, with a net loss of $4.8 million, up from $1.9 million a year earlier, as research and development spending rose to $2.1 million from $0.7 million. The company raised about $8.6 million in gross financing during the quarter, and cash totaled $7.7 million as of June 30, 2026, which it says supports its AKTX-101 development toward a Phase 1 trial planned for mid-2027.
Net loss for Q2 2026 was $4.8 million, compared with $1.9 million in Q2 2025.
R&D expenses were $2.1 million, up from $0.7 million; G&A expenses were $2.5 million, flat year over year.
Financing totaled about $8.6 million gross ($5.5 million private placement plus $3.1 million from warrant exercises), or about $8.0 million net.
Cash was $7.7 million at June 30, 2026, up from $5.2 million at December 31, 2025.
Kodiak Sciences reported a second-quarter 2026 net loss of $65.6 million, or $1.05 per share, up from $54.3 million, or $1.03 per share, a year earlier. Research and development spending rose, and cash fell to $125.9 million at June 30, 2026, which the company says will support operations into 2027.
Net loss for the quarter ended June 30, 2026 was $65.6 million, or $1.05 per share, versus $54.3 million, or $1.03 per share, in Q2 2025.
R&D expenses rose to $56.1 million from $42.8 million, driven by PEAK/PINNACLE clinical activity and Phase 3 manufacturing.
Cash and cash equivalents were $125.9 million at June 30, 2026, down from $209.9 million at December 31, 2025.
Topline DAYBREAK Phase 3 data are expected in September 2026 and PEAK Pivotal Analysis 1 data in December 2026.
Odysight.ai reported first-half 2026 revenue of $0.5 million, down from $2.4 million a year earlier, and a net loss of $9.5 million, up from $8.3 million. The company said revenue is expected to be weighted toward the second half as existing orders convert to deliveries, and backlog rose to $16.45 million as of the release date, including a first purchase order from Boeing.
Revenue was $0.5 million for the six months ended June 30, 2026, versus about $2.4 million in the prior-year period; the prior year included $1.86 million from a Fortune 500 medical company customer in Q1 2025.
Net loss was about $9.5 million for the six months, compared with about $8.3 million a year earlier; operating expenses were about $10.0 million versus $9.7 million.
Backlog was $14.1 million at June 30, 2026 and about $16.45 million as of August 13, 2026, including a first purchase order from Boeing in August 2026.
Cash was about $17.6 million at June 30, 2026, with no debt.
Live Ventures reported fiscal third-quarter results for the quarter ended June 30, 2026. Revenue fell 3.2% to $108.9 million, operating income dropped to $5.3 million from $8.0 million, and the company posted a net loss of $1.1 million, or $0.34 per share, compared with net income of $5.4 million, or $1.24 per diluted share, a year earlier. Shareholders face lower profitability and a loss this quarter, driven mainly by a 29.4% revenue decline in the Retail-Flooring segment.
Revenue was $108.9 million, down 3.2% from $112.5 million; Retail-Flooring revenue fell about $9.0 million, or 29.4%.
Net loss was $1.1 million, or $0.34 per diluted share, versus net income of $5.4 million, or $1.24 per diluted share, a year earlier, which included a $1.5 million Employee Retention Credit gain and a $1.3 million holdback gain.
Adjusted EBITDA was $9.3 million, down 29.5% from $13.2 million; Retail-Entertainment and Steel Manufacturing revenue rose 12.7% and 7.3%.
For the nine months, the net loss was $3.6 million, or $1.16 per share, including a non-cash goodwill impairment of about $4.0 million; about $9.5 million remains under the $10 million share repurchase program.
Saga Communications reported second-quarter 2026 net revenue of $26.4 million, down 6.5% from $28.2 million a year earlier, with net income of $960 thousand and diluted EPS of $0.15 versus $0.18. For the six months, revenue fell 6.0% to $49.3 million and the company posted a net loss of $1.4 million, or $0.23 per diluted share, compared with a $447 thousand loss a year earlier. Shareholders face lower revenue and a six-month loss, partly offset in the quarter by a $1.5 million gain on asset sales.
Q2 2026 net revenue $26.4 million, down 6.5% from $28.2 million; station operating income fell 50.6% to $3.0 million
Q2 2026 net income $960 thousand, diluted EPS $0.15, versus $1.1 million and $0.18 in Q2 2025
Six-month 2026 operating loss of $2.6 million and net loss of $1.4 million, versus $889 thousand and $447 thousand in 2025
Cash and short-term investments were $22.9 million as of August 10, 2026, versus $27.8 million at June 30, 2026, after repaying the $5.0 million revolver in full
Dogwood Therapeutics reported a second-quarter 2026 net loss attributable to common stockholders of $11.5 million, or $0.34 per share, compared with $3.8 million, or $1.99 per share, a year earlier. The loss increase reflects a $9.2 million non-cash IPR&D impairment, and the company reported no revenue in either period. The company said the impairment does not affect its cash runway, which it stated extends through the Phase 2b Halneuron readout in the fourth quarter of 2026.
Q2 2026 net loss of $11.5 million versus $3.8 million in Q2 2025; no revenue in either period
IPR&D impairment of $9.2 million in Q2 2026, partly offset by a $2.5 million deferred tax benefit, for a net impairment of $6.7 million
R&D expenses rose to $3.2 million from $2.6 million; G&A rose to $1.6 million from $1.3 million
Cash of $9.6 million at June 30, 2026, which the company says funds operations through the Phase 2b readout in Q4 2026
Cingulate reported a second-quarter 2026 net loss of $5.9 million, up from $5.0 million a year earlier, as selling, general and administrative expenses rose 101.5% to $3.9 million on commercial readiness spending. The company said its $28.4 million in cash as of June 30, 2026 should fund operations into mid-2027, but the FDA issued a Complete Response Letter for CTx-1301 on June 1, 2026, and resubmission of the NDA depends on finishing manufacturing work.
Q2 2026 net loss was $5.9 million, compared with $5.0 million in Q2 2025
SG&A expenses were $3.9 million, up 101.5%, driven by commercial readiness build-out
R&D expenses fell 44.9% to $1.5 million in the quarter
Cash and cash equivalents were $28.4 million at June 30, 2026, with runway into mid-2027
Candel Therapeutics reported a second-quarter 2026 net loss of $38.9 million, up from $4.8 million a year earlier, as research and development and general and administrative expenses rose and warrant liability fair value changes added $12.2 million of other expense. The company said its $201.6 million in cash and cash equivalents as of June 30, 2026, is expected to fund operations into the first quarter of 2028, and it plans to submit a BLA for aglatimagene in localized prostate cancer in the fourth quarter of 2026.
Q2 2026 net loss was $38.9 million, or $0.52 per share, versus a net loss of $4.8 million, or $0.09 per share, in Q2 2025
R&D expenses rose to $19.8 million from $7.0 million, and G&A expenses rose to $6.9 million from $4.2 million
Cash and cash equivalents were $201.6 million at June 30, 2026, compared with $119.7 million at December 31, 2025
Planned BLA submission for aglatimagene in localized prostate cancer is expected in Q4 2026
Grace Therapeutics reported a net loss of $15.8 million, or $0.91 per share, for the three months ended June 30, 2026, up from $3.4 million, or $0.21 per share, a year earlier. The increase was mainly due to a $13.5 million impairment of in-process research and development tied to GTx-101 and GTx-102, which the company deprioritized in favor of GTx-104. The company also said cash and cash equivalents were $22.2 million as of August 11, 2026, and that existing cash is expected to last through the end of calendar 2028.
Net loss of $15.8 million, or $0.91 per share, versus $3.4 million, or $0.21 per share, in the same period of 2025
$13.5 million impairment of IPR&D for GTx-101 and GTx-102; no impairment was recorded for GTx-104 in the quarter
Cash and cash equivalents of $22.2 million as of August 11, 2026, with cash runway expected through the end of calendar 2028
Company announced a $10 million private placement and said it is pursuing a dual-source manufacturing strategy for the GTx-104 NDA resubmission
Cabaletta Bio reported a second-quarter 2026 net loss of $51.0 million, up from $45.1 million a year earlier, as research and development expenses rose to $44.4 million from $37.6 million. Cash, cash equivalents and short-term investments rose to $225.1 million at June 30, 2026, helped by a May 2026 registered direct offering, and the company expects this to fund operations into mid-2027.
Net loss was $51.0 million for the quarter ended June 30, 2026, versus $45.1 million for the same period in 2025.
Net loss per share was $0.34, compared with $0.73 a year earlier.
R&D expenses were $44.4 million versus $37.6 million; G&A expenses were $7.6 million versus $8.3 million.
Cash and short-term investments were $225.1 million, up from $133.6 million at December 31, 2025; the company expects to fund operations into mid-2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.